Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Hepatitis B, Chronic Clinical Trial

Official title:

A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02631096
• Other study ID #: ARB-001467-002
• Status: Completed
• Phase: Phase 2
• Start date: December 2015
• Est. completion date: May 18, 2018

Study information

• Verified date: June 2018
• Source: Arbutus Biopharma Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467

Description:

Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative subjects and one cohort of HBeAg-positive subjects and 12 HbeAg-negative subjects will be enrolled in cohort 4. All subjects will be non-cirrhotic, with chronic hepatitis B virus (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with entecavir or tenofovir for at least 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: May 18, 2018
• Est. primary completion date: May 18, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Key Inclusion Criteria:

• Documented chronic HBV infection for =12 months prior to Screening Visit.

• Quantitative HBsAg =1000 IU/mL at the Screening Visit.

• Subjects currently receiving entecavir and/or tenofovir for =12 months and HBV DNA undetectable.

Key Exclusion Criteria:

• Known co-infection with HIV, hepatitis C virus, and hepatitis D virus.

• Receiving or planning to receive systemic immunosuppressive medications during the study or =2 months prior to the first dose of study treatment.

• Receiving or planning to receive interferon during the study or =12 months prior to the first dose of study treatment.

• Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia.

• Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine =12 months prior to the Screening Visit.

• Any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings.

Related Conditions & MeSH terms

• Hepatitis B
• Hepatitis B, Chronic

Intervention

Drug:
• ARB-001467
An IV infusion of ARB-001467

Other:
• Placebo
An IV infusion of placebo

Locations

Country	Name	City	State
Australia	Monash Health, Gastroenterology and Hepatology	Clayton	Victoria
Australia	The Alfred, Gastroenterology and Hepatology	Melbourne	Victoria
Australia	Linear Clinical Research Ltd	Nedlands	Western Australia
New Zealand	Auckland Clinical Studies Ltd	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Arbutus Biopharma Corporation

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment.	To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy	28 days post last infusion
Secondary	Evaluate ARB-001467 Maximum plasma concentration (Cmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Secondary	Evaluate ARB-001467 Time to maximum plasma concentration (Tmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Secondary	Evaluate ARB-001467 Area under the plasma concentration-time curve from the start of infusion to the last measurable concentration (AUC0-t) at multiple time points from baseline through Day 85 (cohort 1-3) and Week 36 (Cohort 4).	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Secondary	Evaluate additional parameters for ARB-001467 from plasma concentration-time curve from start of infusion and extrapolated to infinity (AUC0-t), inf) partial, AUCs, T1/2, volume of distribution (VD) and clearance (CL) -baseline through Day 85 or Week 36.	To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.	Up to 36 Weeks
Secondary	Evaluate antiviral activity of ARB 001467 for up to 72 weeks after the first dose of study treatment.	The proportion of subjects in each dose level cohort with =0.5 log10 HBsAg decrease from baseline at EOS, and for these subjects, the changes from baseline (expressed as percentage and log10 change) in the following virologic markers will be assessed throughout the study: Quantitative HBV surface antigen (HBsAg); Quantitative HBV surface antibody (HBsAb); Quantitative HBV DNA and HBV-RNA (viral load); For the HBeAg positive cohort only: - Quantitative HBV e antigen (HBeAg)	Up to 18 months